リスク解析戦略研究センター 医薬品・食品リスク研究グループ
| 1991 年 3 月 | 東京理科大学工学部第一部経営工学科卒業 |
| 1993 年 3 月 | 東京理科大学工学研究科経営工学専攻修士課程修了 |
| 1998 年 3 月 | 東京理科大学工学研究科経営工学専攻博士後期課程満期退学 |
| 1993 年 4 月 | ローヌ・プーランローラー株式会社研究開発本部統計解析室 |
| 1998 年 4 月 | 大分県立看護科学大学看護学部人間科学講座健康情報科学 助手 |
| 2001 年 4 月 | 大分県立看護科学大学看護学部人間科学講座健康情報科学 講師 |
| 2002 年 5 月 | 京都大学大学院医学研究科社会健康医学系専攻薬剤疫学分野 助教授 |
| 2007 年 4 月 | 京都大学大学院医学研究科社会健康医学系専攻薬剤疫学分野 准教授 |
| 2008 年 7 月 | 統計数理研究所データ科学研究系 准教授 |
| 2009 年 10 月 | 統計数理研究所データ科学研究系 教授 |
「再起的事象を対象とした無作為化試験の計画と解析に関する研究」
(2) Matsui, S. and Miyagishi, H. (1999): Design of clinical trials for recurrent events with periodic monitoring, Statistics in Medicine, 18, 3005-3020.
(3) 松井茂之, 宇野一, 小山暢之.(2000): 中間解析における頻度論的アプローチ：最近の理論的展開. 計量生物学, 21巻特集号, 87-124.
(4) 宇野一, 松井茂之, 小山暢之 (2000): 中間解析におけるベイズ流アプローチ：最近の理論的展開. 計量生物学, 21巻特集号, 125-149.
(5) Shinohara, M., Toyokuni, S., Morimoto, T., Matsui, S., Honjo, T. and Shinohara, T. (2003): Functional assessment of self-renewal activity of male germline stem cells following cytotoxic damage and serial transplantation, Biology of Reproduction, 68, 1801-1807.
(6) Matsui, S. (2004): Analysis of times to repeated events in two-arm randomized trials with noncompliance and early withdrawal, Biometrics, 60, 965-976.
(7) Matsui, S., Sadaike, T., Hamada, C. and Fukushima, M. (2005): Creutzfeldt-Jakob disease and cadaveric dura mater grafts in Japan: an updated analysis of incubation time, Neuroepidemiology, 24, 22-25.
(8) Matsui, S. (2005): Sample size calculations for comparative clinical trials with over-dispersed Poisson process data, Statistics in Medicine, 24, 1339-1356.
(9) Sakai, R., Matsui, S., Fukushima, M., Yasuda, H., Miyauchi, H. and Miyachi, Y. (2005): Prognostic factor analysis for plaque psoriasis, Dermatology, 211, 103-106.
(10) Matsui, S. (2005): Stratified analysis in randomized trials with noncompliance, Biometrics, 61, 816-823.
(11) Watanabe, D., Suzuma, K., Matsui, S., Kurimoto, M., Kiryu, J., Kita, M., Suzuma, I., Ohashi, H., Ojima, T., Murakami, T., Kobayashi, T., Masuda, S., Nagao, M., Yoshimura, N. and Takagi, H. (2005): Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy, New England Journal of Medicine, 353, 782-792.
(12) Manzoni, P., Maestri, A., Gomirato, G., Takagi, H., Watanabe, D. and Matsui, S. (2005): Erythropoietin as a retinal angiogenic factor, New England Journal of Medicine, 353, 2190-2191; author reply 2190-2191.
(13) Matsui, S. (2006): Reducing false positive findings in statistical analysis of pharmacogenomic biomarker studies using high-throughput technologies, Current Drug Safety, 1, 135-141.
(14) Matsui, S. (2006): Predicting survival outcomes using subsets of significant genes in prognostic marker studies with microarrays, BMC Bioinformatics, 7, 156.
(15) Nishimura, T., Tada, H., Nakagawa, M., Teramukai, S., Matsui, S. and Fukushima, M. (2006): Lessons from gefitinib-induced interstitial lung disease in Japan and proposal for the prevention of serious drug-induced suffering: Problems in approval, pharmacovigilance, and regulatory decision-making procedures, Pharmacy Practice, 4, 168-178.
(16) Matsui, S., Ito, M., Nishiyama, H., Uno, H., Kotani, H., Watanabe, J., Guilford, P., Reeve, A., Fukushima, M. and Ogawa, O. (2007): Genomic characterization of multiple clinical phenotypes of cancer using multivariate linear regression models, Bioinformatics, 23, 732-738.
(17) Ito, M., Nishiyama, H., Kawanishi, H., Matsui, S., Guilford, P., Reeve, A. and Ogawa, O. (2007): P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer, Journal of Urology, 178, 1073-1079.
(18) Tada, H., Matsui, S., Kawahara, M., Hosoe, S., Hamada, C. and Fukushima, M. (2008): Efficacy, toxicity and cost analysis for non-platinum triplet (gemcitabine and vinorelbine followed by docetaxel) vs. platinum-based chemotherapy in IIIB/IV non-small cell lung cancer: Single institution experience, European Journal of Cancer Care, 17, 120-126.
(19) Matsui, S., Zeng, S., Yamanaka, T. and Shaughnessy, J. (2008): Sample size calculations based on ranking and selection in microarray experiments, Biometrics, 64, 217-226.
(20) Matsui, S., Yamanaka, T., Barlogie, B., Shaughnessy, J. and Crowley, J. (2008): Clustering of significant genes in prognostic studies with microarrays: application to a clinical study for multiple myeloma, Statistics in Medicine, 27, 1106-1120.
(21) Tsubouchi, M., Morishita, R., Tabata, Y., Matsui, S. and Kawakami, K. (2008): Critical issues for effective collaboration between academia and industry in the field of regenerative medicine in Japan, Regenerative Medicine, 3, 497-504.
(22) Tsubouchi, M., Matsui, S., Banno, Y., Kurokawa, K. and Kawakami, K. (2008): Overview of the clinical application of regenerative medicine products in Japan, Health Policy, 88, 62-72.
(23) Yamashita, S., Hbujo, H., Arai, H., Harada-Shiba, M., Matsui, S., Fukushima, M., Saito, Y., Kita, T. and Matsuzawa, Y. (2008): Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan, Journal of Atherosclerosis Thrombosis, 15, 292-303.
(24) Matsui, S. and Oura, T. (2009): Sample sizes for a robust ranking and selection of genes in microarray experiments, Statistics in Medicine, 28, 2801-2816.
(25) Oura, T., Matsui, S. and Kawakami, K. (2009): Sample size calculations for controlling the distribution of false discovery proportion in microarray experiments, Biostatistics, 10, 694-705.
(26) Noma, H., Matsui, S., Omori, T. and Sato, T. (2010): Bayesian ranking and selection methods using hierarchical mixture models in microarray studies, Biostatistics, 11, 281-289.
(27) Noma, H. and Matsui, S. (2010): Optimality of gene ranking based on univariate P-values for detecting differentially expressed genes, Japanese Journal of Biometrics, 31, 13-21.
(28) Yamaguchi, K., Mandai, M., Oura, T., Matsumura, N., Hamanishi, J., Baba, T., Matsui, S., Murphy, S. K. and Konishi, I. (2010): Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes, Oncogene, 29, 1741-1752.
(29) Yoshimura, K., Kamoto, T., Ogawa, O., Matsui, S., Tsuchiya, N., Tada, H., Murata, K., Yoshimura, K., Habuchi, T., and Fukushima, M. (2010): Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: An open-label study, International Journal of Urology, 17, 548-554.
(30) Matsumura, N., Mandai, M., Okamoto, T., Yamaguchi, K., Yamamura, S., Oura, T., Baba, T., Hamanishi, J., Kang, H. S., Matsui, S., Mori, S., Murphy, S. K. and Konishi I. (2010): Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling, Cancer Science, 101, 2658-2663.
(31) Matsui, S. and Noma, H. (2011): Estimation and selection in high-dimensional genomic studies for developing molecular diagnostics, Biostatistics, 12, 223-233.
(32) Sugano, K., Matsumoto, Y., Itabashi, T., Abe, S., Sakaki, N., Ashida, K., Mizokami, Y., Chiba, T., Matsui, S., Kanto, T., Shimada, K., Uchiyama, S., Uemura, N., Hiramatsu, N. for the Lansoprazole Ulcer Prevention Study Group (Low-Dose Aspirin Therapy). (2011): Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term low-dose aspirin therapy: Results of a prospective, multicenter, double-blind, randomized, double-dummy, active-control Trial, Journal of Gastoroenterogy, (In press).
(33) Shoji, S., Suzuki, M., Tomono, Y., Bockbrader, H. N. and Matsui, S. (2011): Population pharmacokinetics of pregabalin in healthy subjects and patients with postherpetic neuralgia or diabetic peripheral neuropathy, British Journal of Clinical Pharmacology, (In press)
(34) Matsui, S. and Noma, H. (2011): Estimating effect sizes of differentially expressed genes for power and sample size assessments in microarray experiments, Biometrics, (In press).
(2) Matsui S. (2006): Statistical applications using DNA microarrays for cancer diagnosis and prognosis, Handbook of Statistics in Clinical Oncology, 2nd edn. (eds J.J. Crowley and D.P. Ankerst), CRC Press, Boca Raton.
Japanese Journal of Clinical Oncology Review Board (2005年−)
Current Drug Safety Editorial Board (2005年−)
日本計量生物学会 理事、評議員（2007年−2012年）
計量生物学 編集委員長（2009−2012年）
Representative Council Member, The International Biometric Society（2011−2014年）
医薬品医療機器総合機構専門委員（2009年−）